- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01867580
A Pilot RCT of Veraflo With Prontosan vs VAC in Wounds Requiring Operative Debridement
July 29, 2022 updated by: 3M
A Prospective, Randomized, Multi-Center Trial Evaluating the Effectiveness of the V.A.C. Ulta Negative Pressure Wound Therapy System With V.A.C. VeraFlo Dressing System in Operatively Debrided Wounds
The purpose of this study is to examine the effectiveness of the Veraflo with Prontosan vs VAC in wounds that require operative debridement.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
181
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Miller School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- St. Luke's University Hospital
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Health System
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
The Subject:
- has a wound prior to informed consent
- will be admitted as an inpatient
- is >= 18 years of age at time of consent
- is able to provide his/her own informed consent
- is willing and able to return for all scheduled and required study visits
- has an open wound >= 4cm in any plane of measurement excluding tunnels after initial surgical debridement
- has a wound that is appropriate for NPWT according to approved indications for use
- has not participated in a clinical trial within the past 30 days
- has a 30 day wound history available if the wound has been previously treated
Exclusion Criteria:
The Subject:
- is pregnant as determined by a positive serum or urine pregnancy test at the time of screening
- has a life expectancy of < 12 months
- is not healthy enough to undergo surgery for any reason
- has, in the investigator's opinion, any clinically significant condition that would impair the participant's ability to comply with the study procedures
- has, in the opinion of the investigator, a condition that will not allow the subject to tolerate the therapy (e.g. painful conditions such as vasculitis)
- has rheumatoid arthritis
- has a bleeding disorder or coagulopathy
- has a wound that contains antibiotic cement or beads
- has an ischemic lower extremity wound as determined by lack of detectable pulses in the extremity or ankle-brachial pressure indices of < 0.9 with a history of diabetes, or < 0.6 if the subject is non-diabetic
- has a known allergy or hypersensitivity to V.A.C. Therapy dressing components including polyurethane or polyvinyl alcohol (drape and foam), or materials that contain acrylic adhesive (drape adhesive)
- has a known allergy or hyper sensitivity to 3M Cavilon No Sting Barrier Film or any of its components including Hexamethyldisiloxane, isooctane, acrylate terpolymer, polyphenylmethysiloxane, copolymer
- has a know allergy or hypersensitivity to Prontosan or any of its components including polyhexamethylene biguanide (PHMB), or undecylenamidopropyl betaine
- has received NPWT on the study wound within the last 30 days
has a wound that is contraindicated with Prontosan
a. presence of hyaline cartilage in the wound
has a wound that is contraindicated with V.A.C. Therapy including:
- malignancy in the wound
- untreated osteomyelitis
- non-enteric or unexplored fistulas
- necrotic tissue with eschar remaining in the wound after debridement (NOTE: Once necrotic tissue or eschar is removed from the wound bed, subjects may be included)
- unprotected, exposed blood vessels, anastomotic sites, organs, or nerves in direct contact with foam
- use of intervening layers between the wound bed and foam
has a wound that is contraindicated with V.A.C. VeraFlo Therapy including:
- Thoracic or abdominal cavities
- Unexplored wounds that may communicate with adjacent body cavities
- has a wound that is closed after the initial debridement
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: V.A.C.Ulta with Prontosan instillation
Treatment Arm
|
NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
|
Active Comparator: V.A.C.Ulta without instillation
Control Arm
|
NPWT only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Inpatient Operating Room Debridements
Time Frame: until the wound is deemed ready for closure or coverage by the investigator up to 64 days
|
Debridement in this outcome refers to surgical removal of non viable tissue performed in an operating room
|
until the wound is deemed ready for closure or coverage by the investigator up to 64 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Difference in Total Bacterial Counts Measured in Colony Forming Units (CFU) as Determined by Quantitative PCR Analysis.
Time Frame: Immediately following initial post debridement to the first dressing change up to 72 hours
|
Immediately following initial post debridement to the first dressing change up to 72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
May 9, 2013
First Submitted That Met QC Criteria
June 3, 2013
First Posted (Estimate)
June 4, 2013
Study Record Updates
Last Update Posted (Actual)
August 1, 2022
Last Update Submitted That Met QC Criteria
July 29, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AHS.2011.ULTA.04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wounds and Injuries
-
3MWithdrawn
-
Centre Hospitalier Universitaire de NīmesCompletedWounds and Injuries, Hands | Wounds and Injuries, Wrists | Wounds and Injuries, Feet | Wounds and Injuries, AnklesFrance
-
Samsung Medical CenterCompletedNeedle Stick InjuriesKorea, Republic of
-
Assaf-Harofeh Medical CenterUnknownInjuries and Wounds
-
Karolinska InstitutetCompletedWounds and Injuries | Blast Injuries | War-Related Injuries | Gunshot WoundSweden
-
Medical University of South CarolinaCompletedNeedlestick InjuriesUnited States
-
Hospital Universiti Sains MalaysiaActive, not recruiting
-
Temple UniversityWithdrawnLacerations | Injuries | WoundsUnited States
-
Acibadem UniversityCompletedNeedlestick InjuriesTurkey
Clinical Trials on V.A.C.Ulta with Prontosan instillation
-
3MTerminatedWounds and Injuries | Wound Healing | Granulation TissueUnited States
-
LifeBridge HealthKinetic Concepts, Inc.CompletedWounds and InjuriesUnited States
-
University of Texas Southwestern Medical CenterWithdrawnFoot Ulcer, DiabeticUnited States
-
University Hospital, GrenobleUnknown
-
Brett CristTerminated
-
University Hospital, Basel, SwitzerlandIBSA Institut Biochimique SARecruitingUrinary Tract Infections | Urinary Tract Infection (UTI)Switzerland
-
HaEmek Medical Center, IsraelUnknown
-
Queen Fabiola Children's University HospitalUnknown
-
Yale UniversityIrrimax CorporationRecruitingUrinary Retention | Neurogenic BladderUnited States
-
St. Luke's-Roosevelt Hospital CenterKinetic Concepts, Inc.CompletedVenous Stasis Ulcers | Lower Extremity Wound InfectedUnited States